CNTB
Connect Biopharma Holdings Limited NASDAQ$2.48
Mkt Cap $140.2M
52w Low $0.70
57.1% of range
52w High $3.82
50d MA $2.74
200d MA $2.27
P/E (TTM)
-2.5x
EV/EBITDA
-2.1x
P/B
3.3x
Debt/Equity
0.0x
ROE
-132.2%
P/FCF
-3.0x
RSI (14)
—
ATR (14)
—
Beta
-0.21
50d MA
$2.74
200d MA
$2.27
Avg Volume
249.4K
About
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.30 | -0.27 | +10.0% | 2.62 | +1.5% | +3.8% | +14.1% | +9.2% | +7.6% | +0.4% | — |
| Aug 13, 2025 | AMC | -0.22 | -0.23 | -4.5% | 2.36 | -0.4% | -8.9% | -13.1% | -18.6% | -23.3% | -29.2% | — |
| Mar 31, 2025 | AMC | -0.27 | -0.06 | +78.7% | 0.55 | +14.5% | +4.0% | +14.7% | +7.3% | +14.5% | +9.1% | — |
| Sep 5, 2024 | AMC | -0.03 | 0.02 | +167.4% | 1.19 | -8.4% | +5.0% | +5.9% | +6.7% | +5.9% | +0.8% | — |
| Apr 16, 2024 | AMC | -0.03 | -0.07 | -131.8% | 1.73 | -4.6% | -10.4% | -12.1% | -11.0% | -22.0% | -19.7% | — |
| Sep 12, 2023 | AMC | -6.92 | -0.08 | +98.9% | 0.76 | -1.0% | +2.9% | +10.8% | +0.3% | -10.3% | -5.3% | — |
| Apr 11, 2023 | AMC | -3.58 | -0.15 | +95.8% | 1.14 | +2.6% | -1.8% | -0.9% | -7.9% | -4.4% | +0.0% | — |
| Sep 13, 2022 | AMC | -5.28 | -0.16 | +96.9% | 1.40 | +0.0% | -1.4% | +4.3% | +2.9% | +0.0% | -0.7% | — |
| Mar 31, 2022 | AMC | -4.38 | -0.17 | +96.2% | 3.02 | +0.3% | +1.0% | +7.6% | -1.0% | +1.0% | +0.7% | — |
| Aug 31, 2021 | AMC | -2.36 | -0.48 | +79.7% | 23.47 | -4.9% | -1.3% | -6.1% | +6.3% | +3.5% | +2.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | BTIG | Maintains | Buy → Buy | — | $2.62 | $2.66 | +1.5% | +3.8% | +14.1% | +9.2% | +7.6% | +0.4% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $2.90 | $2.78 | -4.1% | -9.7% | -6.2% | +3.1% | -1.4% | -2.8% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $1.61 | $1.55 | -3.7% | +4.3% | +31.7% | +54.7% | +59.6% | +95.7% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.27 | $2.46 | +8.4% | +4.0% | -5.3% | -9.7% | -15.4% | -20.3% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.55 | $0.63 | +14.5% | +4.0% | +14.7% | +7.3% | +14.5% | +9.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.68 | $0.68 | +0.0% | -19.1% | -15.9% | -7.3% | -13.2% | -7.4% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.09 | -8.4% | +5.0% | +5.9% | +6.7% | +5.9% | +0.8% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.77 | $1.76 | -0.6% | -5.1% | -9.6% | -6.8% | -15.8% | -18.1% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.65 | -4.6% | -10.4% | -12.1% | -11.0% | -22.0% | -19.7% |
| Sep 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.76 | $0.75 | -1.0% | +2.9% | +10.8% | +0.3% | -10.3% | -5.3% |
Recent Filings
8-K · 8.01
!! High
Connect Biopharma Holdings Limited -- 8-K 8.01: Material Event / Announcement
Connect Biopharma's Data Monitoring Committee completed its interim efficacy review without recommending sample size changes, suggesting the trial is progressing as planned toward potential regulatory approval.
Apr 23
8-K
Unknown — 8-K Filing
Centaur Pharmaceuticals' lead drug shows promising early safety/efficacy data while securing $20.2M funding, extending runway and reducing near-term dilution concerns for investors betting on rademikibart's clinical success.
Mar 31
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CNTB/SMHGF agreed to sell shares through Leerink Partners, likely diluting existing shareholders but providing near-term capital for operations or debt reduction.
Mar 30
Data updated apr 25, 2026 2:20am
· Source: massive.com